JAKi: expanding RMD indications—but important safety concerns to consider ⚠️ Cancer: Neutral vs MTX/placebo, ↑ risk vs TNF ⚠️ Infection: ↑ with age, disease activity & GC use—not uniformly higher with JAKi 🗣️ Patients rank infection risk as top concern @rheumnow #EULAR2025 https://t.co/RJRDWQjqNC